Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

122

Participants

Timeline

Start Date

November 30, 2013

Primary Completion Date

February 14, 2019

Study Completion Date

February 14, 2019

Conditions
Colorectal Cancer
Interventions
DRUG

Minocycline

200 mg by mouth for the first dose, then 100 mg by mouth every 12 hours for 4 months beginning at chemotherapy initiation.

DRUG

Placebo

1 placebo by mouth for the first day of chemotherapy, then 1 dose every 12 hours for 4 months beginning at chemotherapy initiation.

BEHAVIORAL

Questionnaires

Completion of questionnaires at baseline, 1 time each week, at each chemo cycle, at end of treatment visit, and at 6 month follow up visit.

BEHAVIORAL

Sensory Test

Sensory test performed at baseline, 2 months, end of treatment visit, and at 6 month follow up visit.

Trial Locations (2)

77030

LBJ Hospital, Houston

University of Texas MD Anderson Cancer Center, Houston

All Listed Sponsors
collaborator

American Cancer Society, Inc.

OTHER

lead

M.D. Anderson Cancer Center

OTHER

NCT01906008 - Phase II Study of Minocycline for Reducing Symptom Burden in Colorectal Patients | Biotech Hunter | Biotech Hunter